Opendata, web and dolomites

BILITOLERANCE SIGNED

Control of disease tolerance to infection by Biliverdin Reductase A

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BILITOLERANCE project word cloud

Explore the words cloud of the BILITOLERANCE project. It provides you a very rough idea of what is the project "BILITOLERANCE" about.

signals    immune    output    heme    compromising    pathogen    tested    exerting    confer    catabolizing    mechanism    biliverdin    countervailing    said    clearance    expression    pro    enzyme    provides    damage    preserve    hypothesis    sequestering    activation    imposed    central    conserved    primarily    negative    illustrated    infections    tolerance    tissues    receptor    aryl    bilirubin    defense    conversion    fitness    characterizing    functional    lipophilic    unexplored    containment    strategy    cells    relies    mechanisms    immunopathology    shaped    lipid    evolutionary    deleterious    evolution    hydrocarbon    bilitolerance    possibly    infection    ferritin    pathogens    genes    chain    led    bvra    reductase    peroxidation    effector    modulate    tissue    catabolism    anti    survival    potent    carry    direct    parenchyma    oxygenase    presumably    offs    expulsion    macrophages    emergence    health    protein    oxidative    limit    limits    coupled    of    resistance    disease    ahr    stress    function    resident    trade    selective    iron    oxidant    multiple    host    pressure   

Project "BILITOLERANCE" data sheet

The following table provides information about the project.

Coordinator
FUNDACAO CALOUSTE GULBENKIAN 

Organization address
address: AVENIDA BERNA 45
city: LISBOA
postcode: 1000
website: www.igc.gulbenkian.pt

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Total cost 160˙635 €
 EC max contribution 160˙635 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2021-02-04

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACAO CALOUSTE GULBENKIAN PT (LISBOA) coordinator 160˙635.00

Map

 Project objective

The immune system was shaped through evolution, primarily through the selective pressure imposed by pathogens. This led to the emergence of multiple mechanisms that limit the negative impact of pathogens on host health and fitness. The best recognized defense strategy against infections relies on resistance mechanisms that aim at pathogen containment, expulsion or clearance. While crucial for host survival to infection, resistance mechanisms can carry significant trade-offs, often driven by oxidative stress and damage imposed to host parenchyma cells, and in some cases compromising the functional output of host tissues, i.e. immunopathology. Presumably for this reason, resistance mechanisms are coupled to countervailing oxidative stress responses that preserve parenchyma tissue function. These provide tissue damage control without exerting a direct negative impact on pathogens and as such are said to confer disease tolerance to infection. This defense strategy relies on the expression of a number of evolutionary conserved effector genes controlling the pro-oxidant effects of iron and heme, as illustrated for the heme catabolizing enzyme heme oxygenase 1 or the iron sequestering protein ferritin H chain. BILITOLERANCE aims at identifying and characterizing an unexplored and possibly central component of this tissue damage control mechanism that relies on the conversion of the end-product of heme catabolism biliverdin into bilirubin, by biliverdin reductase A (BVRA). The central hypothesis to be tested by BILITOLERANCE is that bilirubin generated by BVRA provides a potent lipophilic anti-oxidant defense mechanism that limits the deleterious effects of lipid peroxidation. Moreover BILITOLERANCE will test the hypothesis that bilirubin also signals via the aryl hydrocarbon receptor (AhR) to modulate the activation of tissue-resident macrophages and promote tissue damage control and disease tolerance to infection.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BILITOLERANCE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BILITOLERANCE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MacMeninges (2019)

Control of Central Nervous Sytem inflammation by meningeal macrophages, and its impairment upon aging

Read More  

5G-ACE (2019)

Beyond 5G: 3D Network Modelling for THz-based Ultra-Fast Small Cells

Read More  

MemoryAggregates (2020)

Mechanism of Whi3 Aggregation and its Age-dependent Malfunction

Read More